FI112117B - Förfarande för mätning av ouabain eller dess analog i plasma - Google Patents

Förfarande för mätning av ouabain eller dess analog i plasma Download PDF

Info

Publication number
FI112117B
FI112117B FI970801A FI970801A FI112117B FI 112117 B FI112117 B FI 112117B FI 970801 A FI970801 A FI 970801A FI 970801 A FI970801 A FI 970801A FI 112117 B FI112117 B FI 112117B
Authority
FI
Finland
Prior art keywords
ouabain
plasma
analog
analogue
compound
Prior art date
Application number
FI970801A
Other languages
English (en)
Finnish (fi)
Other versions
FI970801A (sv
FI970801A0 (sv
Inventor
Pekka Juhani Leppaeluoto
Lauri Erkki Olli Vakkuri
Olli Jaakko Vuolteenaho
Original Assignee
Pekka Juhani Leppaeluoto
Lauri Erkki Olli Vakkuri
Olli Jaakko Vuolteenaho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pekka Juhani Leppaeluoto, Lauri Erkki Olli Vakkuri, Olli Jaakko Vuolteenaho filed Critical Pekka Juhani Leppaeluoto
Publication of FI970801A0 publication Critical patent/FI970801A0/sv
Priority to FI970801A priority Critical patent/FI112117B/sv
Priority to AT98905437T priority patent/ATE254284T1/de
Priority to EP98905437A priority patent/EP0950188B1/en
Priority to AU61018/98A priority patent/AU6101898A/en
Priority to US09/171,797 priority patent/US6190921B1/en
Priority to ES98905437T priority patent/ES2210722T3/es
Priority to PCT/FI1998/000167 priority patent/WO1998038511A1/en
Priority to DE69819682T priority patent/DE69819682T2/de
Publication of FI970801A publication Critical patent/FI970801A/sv
Application granted granted Critical
Publication of FI112117B publication Critical patent/FI112117B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Claims (12)

1. Förfarande för bestämning av ouabain eller dess analog i plasma, för diagnos-10 tisering av hjärt-kärlsjukdomar, endokrina sjukdomar samt andra skadliga tillständ, kännetecknat av att förfarandet omfattar följande steg: (a) ett blodprov tas av objektet som skall undersökas, av vilket prov plasma sepa- reras; (b) ouabain eller dess analog anrikas frän plasmaprovet; 15 (c) en antikropp används som är specifik för ouabain och som har framställts med konjugat av ouabain och bärarprotein, t.ex. tyroglobulin, samt en markörförening som innehäller ouabain eller dess analog, till vilken har tillfogats en förening som ,: har märkts med radiojod eller lantanid; » (d) halien av ouabain eller dess analog i plasmaprovet mäts immunologiskt; och 20 (e) halten av ouabain eller dess analog i steg (c) jämförs med standard för bestäm ning av halten av ouabain eller dess analog i plasma.
2. Förfarande enligt patenkrav 1, kännetecknat av att antikroppen korsreagerar ; ‘:'. mindre än 0,001 % med andra steroider i människans plasma. »
3. Förfarande enligt patentkrav 1, kännetecknat av att ouabainanalog är isomer : > ‘ 25 av ouabain, ouabagenin eller isomer av ouabagenin.
4. Förfarande enligt patentkrav 1, kännetecknat av att radiojod är 125j
5. Förfarande enligt patentkrav 1, kännetecknat av att lantanid är företrädesvis t ‘ europium.
: ' : 6. Förfarande enligt patentkrav 1, kännetecknat av att förening som förbundits 30 till ouabain eller dess analog är L-tyrosin eller poly-L-lysin. 112117
7. Test kit för bestämning av ouabain eller dess analog i plasma, kännetecknad av att den omfattar: (a) polyklonal antikropp mot ouabain eller dess analog som framställts med kon-jugat av ouabain och bärarprotein, t.ex tyroglobulin; 5 (b) markörförening som innehäller ouabain eller dess analog, till vilken har tillfo- gats en förening som märkts med radiojod eller lantanid.
8. Kit enligt patentkrav 7, kännetecknad av att antikroppen korsreagerar under 0,001 % med andra steroider i människans plasma.
9. Kit enligt patentkrav 7, kännetecknad av att ouabainanalog är isomer av oua-10 bain, ouabagenin eller isomer av ouabagenin.
10. Kit enligt patentkrav 7, kännetecknad av att radiojod är 125p
11. Kit enligt patentkrav 7, kännetecknad av att lantanid är företrädesvis europium.
12. Kit enligt patentkrav 7, kännetecknad av att förening som sammanfogats med 15 ouabain eller dess analog är L-tyrosin eller poly-L-lysin. ' * # * ' » » f I ' » I I
FI970801A 1997-02-26 1997-02-26 Förfarande för mätning av ouabain eller dess analog i plasma FI112117B (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FI970801A FI112117B (sv) 1997-02-26 1997-02-26 Förfarande för mätning av ouabain eller dess analog i plasma
US09/171,797 US6190921B1 (en) 1997-02-26 1998-02-25 Ouabain immunoassay and kit and ouabain labeled with 125I or fluorescent label
EP98905437A EP0950188B1 (en) 1997-02-26 1998-02-25 Ouabain immunoassay and kit and ouabain labeled with i125 or fluorescent label
AU61018/98A AU6101898A (en) 1997-02-26 1998-02-25 Ouabain immunoassay and kit and ouabain labeled with i125 or fluorescent label
AT98905437T ATE254284T1 (de) 1997-02-26 1998-02-25 Mit i125 oder fluoreszierenden markern markiertes ouabain und entsprechende immunoassays
ES98905437T ES2210722T3 (es) 1997-02-26 1998-02-25 Inmunoensayo y kit de uabaina y uabaina marcada con i125 o con un marcador fluorescente.
PCT/FI1998/000167 WO1998038511A1 (en) 1997-02-26 1998-02-25 Ouabain immunoassay and kit and ouabain labeled with i125 or fluorescent label
DE69819682T DE69819682T2 (de) 1997-02-26 1998-02-25 Mit i125 oder fluoreszierenden markern markiertes ouabain und entsprechende immunoassays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI970801A FI112117B (sv) 1997-02-26 1997-02-26 Förfarande för mätning av ouabain eller dess analog i plasma
FI970801 1997-02-26

Publications (3)

Publication Number Publication Date
FI970801A0 FI970801A0 (sv) 1997-02-26
FI970801A FI970801A (sv) 1998-08-27
FI112117B true FI112117B (sv) 2003-10-31

Family

ID=8548282

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970801A FI112117B (sv) 1997-02-26 1997-02-26 Förfarande för mätning av ouabain eller dess analog i plasma

Country Status (8)

Country Link
US (1) US6190921B1 (sv)
EP (1) EP0950188B1 (sv)
AT (1) ATE254284T1 (sv)
AU (1) AU6101898A (sv)
DE (1) DE69819682T2 (sv)
ES (1) ES2210722T3 (sv)
FI (1) FI112117B (sv)
WO (1) WO1998038511A1 (sv)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1063702A (en) * 1911-11-08 1913-06-03 Millers Falls Co Chuck.
US1866302A (en) * 1929-02-01 1932-07-05 Gen Zeolite Company Boiler control apparatus
US3959077A (en) * 1970-12-30 1976-05-25 The University Of Southern California Enzyme preparation for serum cardiac glycoside assay
AU2467477A (en) * 1976-05-10 1978-11-02 Beckman Instruments Inc 1125 imidazole steroid derivatives
US4517303A (en) 1982-10-20 1985-05-14 E. I. Du Pont De Nemours And Company Specific binding assays utilizing analyte-cytolysin conjugates
ZA857256B (en) 1984-10-25 1986-05-28 Abbott Lab Fluorescence polarization assay,reagents,and method of making reagents,for determination of digitoxin
EP0218010A3 (en) 1985-07-10 1988-01-07 Abbott Laboratories Ligand detection method and substituted carboxyfluorescein tracers therefor
US4893932A (en) * 1986-05-02 1990-01-16 Particle Measuring Systems, Inc. Surface analysis system and method
US5705402A (en) * 1988-11-03 1998-01-06 Igen International, Inc. Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
US5164296A (en) * 1990-08-31 1992-11-17 University Of Maryland At Baltimore Assay methods involving ouabain
US5206346A (en) 1990-12-05 1993-04-27 E. I. Du Pont De Nemours And Company Method for iodination/purification
US5770376A (en) * 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension

Also Published As

Publication number Publication date
AU6101898A (en) 1998-09-18
DE69819682D1 (de) 2003-12-18
ES2210722T3 (es) 2004-07-01
ATE254284T1 (de) 2003-11-15
US6190921B1 (en) 2001-02-20
WO1998038511A1 (en) 1998-09-03
DE69819682T2 (de) 2004-09-16
EP0950188A1 (en) 1999-10-20
EP0950188B1 (en) 2003-11-12
FI970801A (sv) 1998-08-27
FI970801A0 (sv) 1997-02-26

Similar Documents

Publication Publication Date Title
US6117644A (en) Predicting and detecting cardiac allograft rejection
Jensen et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases
Dockray et al. Amino terminal gastrin fragment in serum of Zollinger-Ellison syndrome patients
US5844091A (en) Antibody having binding specificity for human ouabain
Hughes et al. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction
Lindall et al. Estimation of biologically active intact parathyroid hormone in normal and hyperparathyroid sera by sequential N-terminal immunoextraction and midregion radioimmunoassay
Domin et al. Characterization of neuromedin U like immunoreactivity in rat, porcine guinea-pig and human tissue extracts using a specific radioimmunoassay
MXPA06014775A (es) Metodo de diagnostico para trastornos utilizando copeptina.
Inzitari et al. HPLC‐ESI‐MS analysis of oral human fluids reveals that gingival crevicular fluid is the main source of oral thymosins β4 and β10
US7977072B2 (en) Sandwich immunoassay for identifying partial proANP peptides
Hartter et al. Radioimmunoassay of atrial natriuretic peptides in human plasma.
Hartmann et al. Rapid quantification of C3a and C5a using a combination of chromatographic and immunoassay procedures
DK2333552T3 (en) New biomarkers for non-alcoholic fatty liver, and methods for the detection of non-alcoholic fatty liver using a biomarker
Safieh et al. A new radioimmunoassay for the thymic peptide thymulin, and its application for measuring thymulin in blood samples
Gautvik et al. Development of sequence specific radioimmunoassay of human parathyroid hormone and its use in the diagnosis of hyperparathyroidism
Vakkuri et al. Radioimmunoassay of plasma ouabain in healthy and pregnant individuals
EP0012768A1 (en) QUANTITATIVE DETERMINATION OF VITAMIN B12.
Thody et al. A radioimmunoassay for β-melanocyte-stimulating hormone in human plasma
Togashi et al. Brain natriuretic peptide-like immunoreactivity is present in human plasma
NORTH et al. Isolation and partial characterization of two human neurophysins: Their use in the development of specific radioimmunoassays
Manning et al. Development of homologous immunological assays for human parathyroid hormone
FI112117B (sv) Förfarande för mätning av ouabain eller dess analog i plasma
Ahmed et al. Identification of dynorphin 1–8 in human placenta by mass spectrometry
Anderson et al. Radioimmunoassay of alpha rat atrial natriuretic peptide
Lijnen et al. Endogenous angiotensin I concentration in human plasma

Legal Events

Date Code Title Description
MM Patent lapsed